Zelira Therapeutics Limited (OTCMKTS:ZLDAF) Short Interest Down 16.7% in June

Zelira Therapeutics Limited (OTCMKTS:ZLDAF) saw a significant drop in short interest in June. As of June 15th, there was short interest totalling 500 shares, a drop of 16.7% from the May 31st total of 600 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 5.0 days.

Zelira Therapeutics Stock Performance

Shares of ZLDAF stock opened at $0.19 on Friday. Zelira Therapeutics has a 52-week low of $0.19 and a 52-week high of $1.29. The business’s fifty day moving average is $0.38 and its 200 day moving average is $0.51.

About Zelira Therapeutics

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.